GTR Test Accession:
Help
GTR000568234.3
Last updated in GTR:
2020-08-10
View version history
GTR000568234.3,
last updated:
2020-08-10
GTR000568234.2,
last updated:
2020-08-05
GTR000568234.1,
registered in GTR:
2019-08-14
Last annual review date for the lab: 2024-07-31
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Mutation Confirmation
Conditions (1):
Help
Maturity-onset diabetes of the young type 2
Genes (1):
Help
GCK (7p13)
Methods (2):
Help
Molecular Genetics - Deletion/duplication analysis: Multiplex Ligation-dependent Probe Amplification (MLPA); ...
Target population: Help
Not provided
Clinical validity:
Help
Monogenic diabetes accounts for 2% of all diabetes cases. Until …
Clinical utility:
Help
Establish or confirm diagnosis
Ordering Information
Offered by:
Help
Test short name:
Help
MODY2
Specimen Source:
Help
- Peripheral (whole) blood
Who can order: Help
- Licensed Physician
Test Order Code:
Help
2436
Lab contact:
Help
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Informed consent required:
Help
Decline to answer
Pre-test genetic counseling required:
Help
Decline to answer
Post-test genetic counseling required:
Help
Decline to answer
Recommended fields not provided:
How to Order,
Test strategy,
Test development
Conditions
Help
Total conditions: 1
Condition/Phenotype | Identifier |
---|
Test Targets
Genes
Help
Total genes: 1
Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument *
Deletion/duplication analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
Sequence analysis of the entire coding region
Bi-directional Sanger Sequence Analysis
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Mutation Confirmation
Clinical validity:
Help
Monogenic diabetes accounts for 2% of all diabetes cases. Until
50% of these are due to heterozygous pathogenic variants in the GCK gene. 3.5% of MODY2 cases present partial or total deletion of the gene.
View citations (1)
- Ellard S, Bellanné-Chantelot C, Hattersley AT, . Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546-53. doi:10.1007/s00125-008-0942-y. Epub 2008 Feb 23. PMID: 18297260.
Clinical utility:
Help
Establish or confirm diagnosis
View citations (1)
- Ellard S, Bellanné-Chantelot C, Hattersley AT, . Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546-53. doi:10.1007/s00125-008-0942-y. Epub 2008 Feb 23. PMID: 18297260.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
ACMG-AMP guidelines for the interpretation of sequence variants, 2015 (PMID: 25741868).
ACMG-AMP guidelines for the interpretation of sequence variants, 2015 (PMID: 25741868).
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
Decline to answer.
Decline to answer.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Decline to answer.
Decline to answer.
Recommended fields not provided:
Target population,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
The test was validated using samples of five patients with suspected MODY, finding heterozygous pathogenic variants in GCK in 62.5%. Sanger sequencing of the entire coding region has a sensitivity of almost 100%.
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
No
No
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
PT Provider,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Not provided
Additional Information
Clinical resources:
Molecular resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.